Contract with top 10 global pharmaceutical company

RNS Number : 3166A

IXICO plc

11 September 2018

 

11 September 2018

IXICO plc

("IXICO" or the "Company")

Significant new contract with a top 10 global pharmaceutical company to provide specialist medical imaging services for a Phase III Huntington's disease clinical trial

Highlights the value of IXICO's data science expertise in neuroscience drug development.

IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed a new contract with a top 10 global pharmaceutical company, to provide its technology enabled imaging services in support of a Pivotal Phase III study in Huntington's disease. The contract value of £9.1m will be delivered over a four year term.

As part of this study, IXICO will utilise its expertise to optimise, standardise and collect magnetic resonance imaging (MRI) data from specialist imaging centres across North America, Latin America, Europe, Asia and Australasia. IXICO's data science expertise and artificial intelligence (AI) software algorithms will be applied to provide insights into brain cellular microstructure and neuronal connectivity to support the evaluation of drug safety and efficacy.

This contract expands IXICO's relationship with an existing client and is the fourth new contract in Huntington's disease announced this financial year. It demonstrates the increasing adoption of IXICO's scientific and operational expertise in this important area of clinical development; Huntington's disease is a rare genetic neurodegenerative disorder which affects movement, cognition and behaviour.

Giulio Cerroni, CEO of IXICO, said: "I am delighted to announce this new contract for a Pivotal Phase III clinical trial with an existing client which demonstrates confidence in IXICO's services to deliver valuable insights through our proprietary data analytics platform. Huntington's disease is an area of significant unmet medical need as there are currently no effective marketed treatments. This latest contract award reflects our experience working in this important area of neuroscience drug development which, together with previously announced new contracts and contract extensions, provides a strong foundation for future growth."

For further information please contact:

IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer	Tel: [phone]
Shore Capital (Nomad and Broker) Edward Mansfield / Anita Ghanekar / Daniel Bush	Tel: [phone]
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan	Tel: [phone]

About IXICO

IXICO is dedicated to delivering insights in neuroscience.   Our mission is to transform the progression of our clients' neurodegenerative therapeutic pipeline through the application of advanced medical imaging and digital health technologies.

IXICO's specialist data analytics services are used by the global pharmaceutical industry to analyse brain scan data and digital biomarkers to measure disease status and progression, enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical trial process evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

 

END

 

 

CNTEALNEFAAPEFF